Activity of Ibrutinib in Mantle Cell Lymphoma Patients with Central Nervous System Relapse

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2015 Aug 5

PMID 26239089

Citations 66

Authors

Sophie Bernard

Lauriane Goldwirt

Sandy Amorim

Pauline Brice

Josette Briere

Eric De Kerviler

Samia Mourah

Helene Sauvageon

Catherine Thieblemont

Affiliations

Soon will be listed here.

Abstract

The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibrutinib, an oral inhibitor of Bruton tyrosine kinase, shows great promise. Here we report the clinical observation of 3 MCL patients with symptomatic CNS relapse treated with single-agent ibrutinib. All 3 patients had dramatic and rapid responses with almost immediate recovery from symptoms. We also confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method. All responses were ongoing after 2 months to 1 year of follow-up.

Citing Articles

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.

Robak T, Pula A, Braun M, Robak E Ann Hematol. 2024; 103(9):3369-3383.

PMID: 39052034 PMC: 11358350. DOI: 10.1007/s00277-024-05854-1.

A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.

Grommes C, Nandakumar S, Schaff L, Gavrilovic I, Kaley T, Nolan C Clin Cancer Res. 2024; 30(18):4005-4015.

PMID: 38995739 PMC: 11398981. DOI: 10.1158/1078-0432.CCR-24-0605.

Testicular involvement in mantle cell lymphoma: An analysis of 16 patients.

Alkhalili S, Manogna D, Safah H, Ellent E, Beversdorf W, Arora R Leuk Res Rep. 2023; 20:100397.

PMID: 38053743 PMC: 10694562. DOI: 10.1016/j.lrr.2023.100397.

Leukemic infiltration of the optic nerve in chronic lymphocytic leukemia: A case report and review of literature.

Liu L, Hadyah S, Park A, Akhtari M, Scott J, Ran-Castillo D Leuk Res Rep. 2023; 20:100391.

PMID: 37711672 PMC: 10498303. DOI: 10.1016/j.lrr.2023.100391.

How I treat secondary CNS involvement by aggressive lymphomas.

Alderuccio J, Nayak L, Cwynarski K Blood. 2023; 142(21):1771-1783.

PMID: 37702537 PMC: 10862244. DOI: 10.1182/blood.2023020168.

References

Hendriks R, Yuvaraj S, Kil L . Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014; 14(4):219-32. DOI: 10.1038/nrc3702. View

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

Aviles A, Jesus Nambo M, Neri N . Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol. 2013; 30(2):520. DOI: 10.1007/s12032-013-0520-0. View

Advani R, Buggy J, Sharman J, Smith S, Boyd T, Grant B . Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2012; 31(1):88-94. PMC: 5505166. DOI: 10.1200/JCO.2012.42.7906. View

Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-80. PMC: 2919935. DOI: 10.1073/pnas.1004594107. View

Shah V, Midha K, Findlay J, HILL H, Hulse J, McGilveray I . Bioanalytical method validation--a revisit with a decade of progress. Pharm Res. 2001; 17(12):1551-7. DOI: 10.1023/a:1007669411738. View

Wang M, Blum K, Martin P, Goy A, Auer R, Kahl B . Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6):739-45. PMC: 4528064. DOI: 10.1182/blood-2015-03-635326. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Campo E, Rule S . Mantle cell lymphoma: evolving management strategies. Blood. 2014; 125(1):48-55. DOI: 10.1182/blood-2014-05-521898. View

10.

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

11.

Cheah C, George A, Gine E, Chiappella A, Kluin-Nelemans H, Jurczak W . Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013; 24(8):2119-23. DOI: 10.1093/annonc/mdt139. View

12.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

13.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg J, Amorim S . Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014; 15(9):1019-26. DOI: 10.1016/S1470-2045(14)70311-0. View